These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 32885390)

  • 1. Anakinra for Treatment-Resistant Kawasaki Disease: Evidence from a Literature Review.
    Ferrara G; Giani T; Caparello MC; Farella C; Gamalero L; Cimaz R
    Paediatr Drugs; 2020 Dec; 22(6):645-652. PubMed ID: 32885390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial).
    Tremoulet AH; Jain S; Kim S; Newburger J; Arditi M; Franco A; Best B; Burns JC
    Contemp Clin Trials; 2016 May; 48():70-5. PubMed ID: 27080929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A child with resistant Kawasaki disease successfully treated with anakinra: a case report.
    Sánchez-Manubens J; Gelman A; Franch N; Teodoro S; Palacios JR; Rudi N; Rivera J; Antón J
    BMC Pediatr; 2017 Apr; 17(1):102. PubMed ID: 28390409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II Open Label Study of Anakinra in Intravenous Immunoglobulin-Resistant Kawasaki Disease.
    Koné-Paut I; Tellier S; Belot A; Brochard K; Guitton C; Marie I; Meinzer U; Cherqaoui B; Galeotti C; Boukhedouni N; Agostini H; Arditi M; Lambert V; Piedvache C
    Arthritis Rheumatol; 2021 Jan; 73(1):151-161. PubMed ID: 32779863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Immunological Axis Involving Interleukin 1β and Leucine-Rich-α2-Glycoprotein Reflects Therapeutic Response of Children with Kawasaki Disease: Implications from the KAWAKINRA Trial.
    Kessel C; Koné-Paut I; Tellier S; Belot A; Masjosthusmann K; Wittkowski H; Fuehner S; Rossi-Semerano L; Dusser P; Marie I; Boukhedouni N; Agostini H; Piedvache C; Foell D
    J Clin Immunol; 2022 Aug; 42(6):1330-1341. PubMed ID: 35699824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: A retrospective cases series.
    Kone-Paut I; Cimaz R; Herberg J; Bates O; Carbasse A; Saulnier JP; Maggio MC; Anton J; Piram M
    Autoimmun Rev; 2018 Aug; 17(8):768-774. PubMed ID: 29885546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Comprehensive Update on Kawasaki Disease Vasculitis and Myocarditis.
    Soni PR; Noval Rivas M; Arditi M
    Curr Rheumatol Rep; 2020 Feb; 22(2):6. PubMed ID: 32020498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-1 receptor antagonist, anakinra, prevents myocardial dysfunction in a mouse model of Kawasaki disease vasculitis and myocarditis.
    Gorelik M; Lee Y; Abe M; Andrews T; Davis L; Patterson J; Chen S; Crother TR; Aune GJ; Noval Rivas M; Arditi M
    Clin Exp Immunol; 2019 Oct; 198(1):101-110. PubMed ID: 31099056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kawasaki disease: a comprehensive review of treatment options.
    Patel RM; Shulman ST
    J Clin Pharm Ther; 2015 Dec; 40(6):620-5. PubMed ID: 26547265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anakinra And Etanercept Combination Treatment in a Child With Severe, Nonresponsive Kawasaki Disease.
    Walser M; Hermann M; Hufnagel M; Haas NA; Fischer M; Dalla-Pozza R; Jakob A
    Pediatr Infect Dis J; 2020 Oct; 39(10):e310-e313. PubMed ID: 32618930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-1 Beta-Mediated Sex Differences in Kawasaki Disease Vasculitis Development and Response to Treatment.
    Porritt RA; Markman JL; Maruyama D; Kocaturk B; Chen S; Lehman TJA; Lee Y; Fishbein MC; Noval Rivas M; Arditi M
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):802-818. PubMed ID: 31996019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of IL-6 in the LCWE Mouse Model of Kawasaki Disease Inhibits Acute Phase Reactant Serum Amyloid A but Fails to Attenuate Vasculitis.
    Porritt RA; Chase Huizar C; Dick EJ; Kumar S; Escalona R; Gomez AC; Marek-Iannucci S; Noval Rivas M; Patterson J; Forsthuber TG; Arditi M; Gorelik M
    Front Immunol; 2021; 12():630196. PubMed ID: 33897686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anakinra in the treatment of Kawasaki disease: mechanisms, efficacy and safety].
    Tong T; Wang YJ; Gong FQ
    Zhonghua Er Ke Za Zhi; 2021 Nov; 59(11):997-1000. PubMed ID: 34711041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during SARS-CoV-2 epidemic in Italy: results from a national, multicenter survey.
    Cattalini M; Della Paolera S; Zunica F; Bracaglia C; Giangreco M; Verdoni L; Meini A; Sottile R; Caorsi R; Zuccotti G; Fabi M; Montin D; Meneghel A; Consolaro A; Dellepiane RM; Maggio MC; La Torre F; Marchesi A; Simonini G; Villani A; Cimaz R; Ravelli A; Taddio A;
    Pediatr Rheumatol Online J; 2021 Mar; 19(1):29. PubMed ID: 33726806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High dose Anakinra for treatment of severe neonatal Kawasaki disease: a case report.
    Shafferman A; Birmingham JD; Cron RQ
    Pediatr Rheumatol Online J; 2014; 12():26. PubMed ID: 25045337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-1-dependent electrophysiological changes and cardiac neural remodeling in a mouse model of Kawasaki disease vasculitis.
    Abe M; Rastelli DD; Gomez AC; Cingolani E; Lee Y; Soni PR; Fishbein MC; Lehman TJA; Shimada K; Crother TR; Chen S; Noval Rivas M; Arditi M
    Clin Exp Immunol; 2020 Mar; 199(3):303-313. PubMed ID: 31758701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kawasaki disease: 40 years after the original report.
    Gedalia A
    Curr Rheumatol Rep; 2007 Aug; 9(4):336-41. PubMed ID: 17688844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance.
    Fury W; Tremoulet AH; Watson VE; Best BM; Shimizu C; Hamilton J; Kanegaye JT; Wei Y; Kao C; Mellis S; Lin C; Burns JC
    Hum Immunol; 2010 Sep; 71(9):865-73. PubMed ID: 20600450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A low-frequency IL4R locus variant in Japanese patients with intravenous immunoglobulin therapy-unresponsive Kawasaki disease.
    Amano Y; Akazawa Y; Yasuda J; Yoshino K; Kojima K; Kobayashi N; Matsuzaki S; Nagasaki M; Kawai Y; Minegishi N; Ishida N; Motoki N; Hachiya A; Nakazawa Y; Yamamoto M; Koike K; Takeshita T
    Pediatr Rheumatol Online J; 2019 Jul; 17(1):34. PubMed ID: 31269967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
    Kuo HC; Lo MH; Hsieh KS; Guo MM; Huang YH
    PLoS One; 2015; 10(12):e0144603. PubMed ID: 26658843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.